secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0000950170-24-001488
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome reports preliminary Q4 net product revenue of $71M; full year $204M
--------------------------------------------------------------------------

- Preliminary total net product revenue: $71M for Q4 2023, $204M for full year 2023.
- Auvelity net sales: $49M Q4, $130M FY; Sunosi net revenue: $22M Q4, $74M FY.
- 2024 regulatory milestones: NDA submission for AXS-14 (fibromyalgia) Q1; NDA resubmission for AXS-07 (migraine) H1.
- 2024 clinical readouts: Phase 3 SYMPHONY (narcolepsy) Q1, ADVANCE-2 (Alzheimer's agitation) H1, FOCUS (ADHD) H2.
- 2024 trial initiations: Phase 3 solriamfetol for MDD, BED, SWD Q1; Phase 2/3 AXS-05 for smoking cessation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024001488/0000950170-24-001488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024001488/axsm-20240104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-001488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer